$LCTX
Lineage Cell Therapeutics, Inc.
XASE•Health Care•Biological Products, (No Diagnostic Substances)
$0.973
▲+2.08%+$0.020
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateLineage Cell Therapeutics, Inc.
XASE•Health Care•Biological Products, (No Diagnostic Substances)
Why is LCTX up today? It is at $0.973 (+2.08%), and our scanner flagged it 91 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment LCTX spikes, and full due diligence on LCTX — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $LCTX 91 times in the last 30 days. Create a free account to track $LCTX, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
LCTX is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 2 unusual-volume and momentum alerts on LCTX today, peaking at 6.0x its normal volume.
Likely catalystLineage Cell Therapeutics, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Across every filing on file, supply equal to 289.2% of the tradeable float is in play - 106.6% has already been sold, and 182.7% more can still be issued.
Shelf sizes are dollars, so shares are estimated at today's price.
One filing exceeds the whole float, which usually means our share count is stale. Check the filing directly.
Recent share offering + active shelf on file — the company raised capital and can raise more
60,000,000 new shares
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Culley Brian M Officer | Bought (open market) | +15K | added 6.2% | 256K | $24K at $1.62 | Mar 12, 26 |
Culley Brian M Officer | Sold (automatic/other) | -13K | sold 5.1% | 241K | $23K at $1.80 | Feb 11, 26 |
Culley Brian M Officer | Other | 31K 0.01% of company | added 14% | 253K | n/a | Feb 11, 26 |
Samuel George A. Iii Officer | Sold (automatic/other) | -3K | sold 7.5% | 31K | $5K at $1.80 | Feb 11, 26 |
Samuel George A. Iii Officer | Other | 6K | added 22% | 34K | n/a | Feb 11, 26 |
Samuel George A. Iii Officer | Acquired (grant/award) | +2K | added 6.7% | 28K | n/a | Dec 19, 25 |
Samuel George A. Iii Officer | Sold (automatic/other) | -65 | sold 0.2% | 27K | $109 at $1.68 | Dec 19, 25 |
Culley Brian M Officer | Acquired (grant/award) | +9K | added 4.2% | 222K | n/a | Dec 19, 25 |
Culley Brian M Officer | Sold (automatic/other) | -334 | sold 0.2% | 222K | $561 at $1.68 | Dec 19, 25 |
Culley Brian M Officer | Sold (automatic/other) | -13K | sold 5.5% | 214K | $8K at $0.650 | Feb 11, 25 |
Culley Brian M Officer | Other | 31K 0.01% of company | added 16% | 226K | n/a | Feb 11, 25 |
Samuel George A. Iii Officer | Sold (automatic/other) | -2K | sold 8.6% | 26K | $2K at $0.650 | Feb 11, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in biological products, (no diagnostic substances), closest in size first.
LCTX is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 2 unusual-volume and momentum alerts on LCTX today, peaking at 6.0x its normal volume.
LCTX last traded at $0.973, up 2.08% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Lineage Cell Therapeutics, Inc. (LCTX) is next expected to report earnings on Thursday, November 5, 2026, about 16 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The LCTX Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged LCTX 91 times in the last 30 days.
LCTX (Lineage Cell Therapeutics, Inc.) trades on XASE, with a market cap of about $241M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge LCTX for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$LCTX discussion
Sign in to ask a question or join the discussion.